Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE-30: Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma
NCT07497607Phase 2Recruiting
- Sponsor
- Sara Medek
- Start
- May 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Sara Medek. Primary endpoint: Progression-Free Survival at 2 years. Started May 2026; status: recruiting.
02
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07497607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497607.